Royalty Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	2,378	2,264	2,355	2,237	2,289
Revenue Growth (YoY)	5.06%	-3.86%	5.24%	-2.28%	7.87%
Cost of Revenue	-295.84	732.46	560.66	904.24	452.84
Gross Profit	2,674	1,531	1,794	1,333	1,837
Selling, General & Admin	573.48	236.67	249.75	227.3	182.83
Depreciation & Amortization Expenses	-	-	-	5.67	23
Research & Development	452	2	52	177.11	200.08
Other Operating Expenses	89.03	-	-	615.83	-
Total Operating Expenses	1,115	238.67	301.75	1,026	405.91
Operating Income	1,560	1,292	1,492	307.07	1,431
Interest Income	33.59	47.34	72.29	78.34	53.54
Interest Expense	-307.66	-225.51	-187.19	-187.96	-166.14
Other Non-Operating Income (Expense)	-111.15	-140.5	-192.03	50.57	-37.93
Total Non-Operating Income (Expense)	-385.22	-318.67	-306.93	-59.06	-150.53
Pretax Income	1,324	1,331	1,700	230.06	1,241
Net Income	770.95	858.98	1,135	42.83	619.73
Minority Interest in Earnings	553.25	471.83	565.25	187.23	621.47
Net Income to Common	770.95	858.98	1,135	42.83	619.73
Net Income Growth	-10.25%	-24.31%	2549.50%	-93.09%	-36.44%
Shares Outstanding (Basic)	430	448	448	438	415
Shares Outstanding (Diluted)	564	594	603	438	415
Shares Change (YoY)	-4.99%	-1.46%	37.66%	5.59%	-43.84%
EPS (Basic)	1.79	1.92	2.54	0.10	1.49
EPS (Diluted)	1.78	1.91	2.53	0.10	1.49
EPS Growth	-6.81%	-24.51%	2430.00%	-93.29%	12.88%
Free Cash Flow	2,490	2,769	2,988	2,144	2,018
Free Cash Flow Growth	-10.08%	-7.32%	39.36%	6.27%	-0.84%
Free Cash Flow Per Share	4.41	4.66	4.96	4.90	4.86
Dividends Per Share	0.880	0.840	0.800	0.760	0.680
Dividend Growth	4.76%	5.00%	5.26%	11.77%	126.67%
Gross Margin	112.44%	67.64%	76.19%	59.58%	80.22%
Operating Margin	65.58%	57.10%	63.37%	13.73%	62.49%
Profit Margin	55.68%	58.79%	72.20%	10.28%	54.21%
FCF Margin	104.69%	122.33%	126.89%	95.83%	88.12%
EBITDA	1,563	1,292	1,492	307.07	1,431
EBITDA Margin	65.74%	57.10%	63.37%	13.73%	62.49%
EBIT	1,560	1,292	1,492	307.07	1,431
EBIT Margin	65.58%	57.10%	63.37%	13.73%	62.49%

Updated Feb 11, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q